药物对比
Ertugliflozin vs Troglitazone
比较 Ertugliflozin（Steglatro，SGLT2抑制剂）与 Troglitazone（已退市的TZD）治疗2型糖尿病。解析安全性、疗效及可获得性的差异。
此页面暂无可用的对比维度。
临床背景
This comparison occurs when patients or clinicians review historical TZD options against current SGLT2 inhibitors for type 2 diabetes.
结论
Ertugliflozin is a currently used SGLT2 inhibitor while Troglitazone is unavailable due to severe liver risks.
全部药物对比